Cargando…
Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?
BACKGROUND: Genuine uncertainty on superiority of one intervention over the other is called equipoise. Physician-investigators in randomized controlled trials (RCT) need equipoise at least in studies with more than minimal risks. Ideally, this equipoise is also present in patient-participants. In pe...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302476/ https://www.ncbi.nlm.nih.gov/pubmed/30572875 http://dx.doi.org/10.1186/s12910-018-0336-8 |
_version_ | 1783381988230561792 |
---|---|
author | Hissink Muller, Petra C. E. Yildiz, Bahar Allaart, Cornelia F. Brinkman, Danielle M. C. van Rossum, Marion van Suijlekom-Smit, Lisette W. A. van den Berg, J. Merlijn ten Cate, Rebecca de Vries, Martine C. |
author_facet | Hissink Muller, Petra C. E. Yildiz, Bahar Allaart, Cornelia F. Brinkman, Danielle M. C. van Rossum, Marion van Suijlekom-Smit, Lisette W. A. van den Berg, J. Merlijn ten Cate, Rebecca de Vries, Martine C. |
author_sort | Hissink Muller, Petra C. E. |
collection | PubMed |
description | BACKGROUND: Genuine uncertainty on superiority of one intervention over the other is called equipoise. Physician-investigators in randomized controlled trials (RCT) need equipoise at least in studies with more than minimal risks. Ideally, this equipoise is also present in patient-participants. In pediatrics, data on equipoise are lacking. We hypothesize that 1) lack of equipoise at enrolment among parents may reduce recruitment; 2) lack of equipoise during participation may reduce retention in patients assigned to a less favoured treatment-strategy. METHODS: We compared preferences of parents/patients at enrolment, documented by a questionnaire (phase 1), with preferences developed during follow-up by an interview-study (phase 2) to investigate equipoise of child-participants and parents in the BeSt-for-Kids-study (NTR 1574). This trial in new-onset Juvenile Idiopathic Arthritis-patients consists of three strategies. One strategy comprises initial treatment with a biological disease-modifying-antirheumatic-drug (DMARD), currently not standard-of-care. Semi-structured interviews were conducted with 23 parents and 7 patients, median 11 months after enrolment. RESULTS: Initially most parents and children were not in equipoise. Parents/patients who refused participation, regularly declined due to specific preferences. Many participating families preferred the biological-first-strategy. They participated to have a chance for this initial treatment, and would even consider stopping trial-participation when not randomized for it. Their conviction of superiority of the biological-first strategy was based on knowledge from internet and close relations. According to four parents, the physician-investigator preferred the biological-first-strategy, but the majority (n = 19) stated that she had no preferred strategy. In phase 2, preferences tended to change to the treatment actually received. CONCLUSIONS: Lack of equipoise during enrolment did not reduce study recruitment, mainly due to the fact that preferred treatment was only available within the study. Still, when developing a trial it is important to evaluate whether the physicians’ research question is in line with preferences of the patient-group. By exploring so-called ‘informed patient-group’-equipoise, successful recruitment may be enhanced and bias avoided. In our study, lack of equipoise during trial-participation did not reduce retention in those assigned to a less favoured option. We observed a change for preference towards treatment actually received, possibly explained by comparable outcomes in all three arms. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12910-018-0336-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6302476 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63024762018-12-31 Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise? Hissink Muller, Petra C. E. Yildiz, Bahar Allaart, Cornelia F. Brinkman, Danielle M. C. van Rossum, Marion van Suijlekom-Smit, Lisette W. A. van den Berg, J. Merlijn ten Cate, Rebecca de Vries, Martine C. BMC Med Ethics Research Article BACKGROUND: Genuine uncertainty on superiority of one intervention over the other is called equipoise. Physician-investigators in randomized controlled trials (RCT) need equipoise at least in studies with more than minimal risks. Ideally, this equipoise is also present in patient-participants. In pediatrics, data on equipoise are lacking. We hypothesize that 1) lack of equipoise at enrolment among parents may reduce recruitment; 2) lack of equipoise during participation may reduce retention in patients assigned to a less favoured treatment-strategy. METHODS: We compared preferences of parents/patients at enrolment, documented by a questionnaire (phase 1), with preferences developed during follow-up by an interview-study (phase 2) to investigate equipoise of child-participants and parents in the BeSt-for-Kids-study (NTR 1574). This trial in new-onset Juvenile Idiopathic Arthritis-patients consists of three strategies. One strategy comprises initial treatment with a biological disease-modifying-antirheumatic-drug (DMARD), currently not standard-of-care. Semi-structured interviews were conducted with 23 parents and 7 patients, median 11 months after enrolment. RESULTS: Initially most parents and children were not in equipoise. Parents/patients who refused participation, regularly declined due to specific preferences. Many participating families preferred the biological-first-strategy. They participated to have a chance for this initial treatment, and would even consider stopping trial-participation when not randomized for it. Their conviction of superiority of the biological-first strategy was based on knowledge from internet and close relations. According to four parents, the physician-investigator preferred the biological-first-strategy, but the majority (n = 19) stated that she had no preferred strategy. In phase 2, preferences tended to change to the treatment actually received. CONCLUSIONS: Lack of equipoise during enrolment did not reduce study recruitment, mainly due to the fact that preferred treatment was only available within the study. Still, when developing a trial it is important to evaluate whether the physicians’ research question is in line with preferences of the patient-group. By exploring so-called ‘informed patient-group’-equipoise, successful recruitment may be enhanced and bias avoided. In our study, lack of equipoise during trial-participation did not reduce retention in those assigned to a less favoured option. We observed a change for preference towards treatment actually received, possibly explained by comparable outcomes in all three arms. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12910-018-0336-8) contains supplementary material, which is available to authorized users. BioMed Central 2018-12-20 /pmc/articles/PMC6302476/ /pubmed/30572875 http://dx.doi.org/10.1186/s12910-018-0336-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Hissink Muller, Petra C. E. Yildiz, Bahar Allaart, Cornelia F. Brinkman, Danielle M. C. van Rossum, Marion van Suijlekom-Smit, Lisette W. A. van den Berg, J. Merlijn ten Cate, Rebecca de Vries, Martine C. Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise? |
title | Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise? |
title_full | Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise? |
title_fullStr | Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise? |
title_full_unstemmed | Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise? |
title_short | Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise? |
title_sort | participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302476/ https://www.ncbi.nlm.nih.gov/pubmed/30572875 http://dx.doi.org/10.1186/s12910-018-0336-8 |
work_keys_str_mv | AT hissinkmullerpetrace participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise AT yildizbahar participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise AT allaartcorneliaf participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise AT brinkmandaniellemc participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise AT vanrossummarion participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise AT vansuijlekomsmitlisettewa participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise AT vandenbergjmerlijn participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise AT tencaterebecca participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise AT devriesmartinec participationinasingleblindedpediatrictherapeuticstrategystudyforjuvenileidiopathicarthritisareparentsandpatientparticipantsinequipoise |